Response to Chen and Liaw

Hsin-Che Lin,Wen-Juei Jeng,Hwai-I Yang

DOI: https://doi.org/10.14309/ctg.0000000000000663

2024-03-28

Clinical and Translational Gastroenterology

Abstract:We appreciate the opportunity to discuss the important points raised regarding our study on hepatitis B surface antigen (HBsAg) seroclearance prediction ( 1,2 ). First, questions were raised about whether an annual HBsAg decline rate >0.5 log 10 IU/mL alone could be predictive for HBsAg seroclearance among patients with various HBsAg levels. Indeed, our data indicate that patients who achieved HBsAg clearance within 1 year and those with an annual HBsAg decline rate >0.5 log 10 IU/mL, all had HBsAg level 200 IU/mL could not be validly assessed by our study. However, our data also suggest that reducing HBsAg levels to below 200 IU/mL seems to be a prerequisite for short-term HBsAg seroclearance within 1 year, and an annual HBsAg decline rate of >0.5 log 10 IU/mL alone may embody the characteristics of both absolute HBsAg levels and decline rate. The study by Seto et al ( 3 ) also found that nearly all patients (98.3%) had HBsAg level <100 IU/mL 1 year before HBsAg clearance. While their study examined the kinetics of HBsAg levels up to 3 years before seroclearance, their findings indicate that an annual reduction in HBsAg of 0.5 log provides the greatest predictive value for HBsAg seroclearance, including those with serum HBsAg levels greater than 200 IU/mL. Nevertheless, we acknowledge the need for additional data to solidify our conclusion further.

gastroenterology & hepatology